240 related articles for article (PubMed ID: 28272130)
1. Pharmacological Treatment of ADHD in Addicted Patients: What Does the Literature Tell Us?
Carpentier PJ; Levin FR
Harv Rev Psychiatry; 2017; 25(2):50-64. PubMed ID: 28272130
[TBL] [Abstract][Full Text] [Related]
2. The clinical dilemma of using medications in substance-abusing adolescents and adults with attention-deficit/hyperactivity disorder: what does the literature tell us?
Wilens TE; Monuteaux MC; Snyder LE; Moore H; Whitley J; Gignac M
J Child Adolesc Psychopharmacol; 2005 Oct; 15(5):787-98. PubMed ID: 16262595
[TBL] [Abstract][Full Text] [Related]
3. Pharmacotherapeutic strategies for the treatment of attention-deficit hyperactivity (ADHD) disorder with comorbid substance-use disorder (SUD).
Perugi G; Pallucchini A; Rizzato S; De Rossi P; Sani G; Maremmani AG; Pinzone V; Maremmani I
Expert Opin Pharmacother; 2019 Feb; 20(3):343-355. PubMed ID: 30513231
[TBL] [Abstract][Full Text] [Related]
4. International Consensus Statement for the Screening, Diagnosis, and Treatment of Adolescents with Concurrent Attention-Deficit/Hyperactivity Disorder and Substance Use Disorder.
Özgen H; Spijkerman R; Noack M; Holtmann M; Schellekens ASA; van de Glind G; Banaschewski T; Barta C; Begeman A; Casas M; Crunelle CL; Daigre Blanco C; Dalsgaard S; Demetrovics Z; den Boer J; Dom G; Eapen V; Faraone SV; Franck J; González RA; Grau-López L; Groenman AP; Hemphälä M; Icick R; Johnson B; Kaess M; Kapitány-Fövény M; Kasinathan JG; Kaye SS; Kiefer F; Konstenius M; Levin FR; Luderer M; Martinotti G; Matthys FIA; Meszaros G; Moggi F; Munasur-Naidoo AP; Post M; Rabinovitz S; Ramos-Quiroga JA; Sala R; Shafi A; Slobodin O; Staal WG; Thomasius R; Truter I; van Kernebeek MW; Velez-Pastrana MC; Vollstädt-Klein S; Vorspan F; Young JT; Yule A; van den Brink W; Hendriks V
Eur Addict Res; 2020; 26(4-5):223-232. PubMed ID: 32634814
[TBL] [Abstract][Full Text] [Related]
5. Pharmacological treatment of attention deficit hyperactivity disorder with co-morbid drug dependence.
Cunill R; Castells X; Tobias A; Capellà D
J Psychopharmacol; 2015 Jan; 29(1):15-23. PubMed ID: 25142405
[TBL] [Abstract][Full Text] [Related]
6. Prevalence and characteristics of South African treatment-seeking patients with substance use disorder and co-occurring attention-deficit/hyperactivity disorder.
Coetzee C; Truter I; Meyer A
Expert Rev Clin Pharmacol; 2020 Nov; 13(11):1271-1280. PubMed ID: 33040639
[TBL] [Abstract][Full Text] [Related]
7. Managing attention-deficit/hyperactivity disorder in the presence of substance use disorder.
Upadhyaya HP
J Clin Psychiatry; 2007; 68 Suppl 11():23-30. PubMed ID: 18307378
[TBL] [Abstract][Full Text] [Related]
8. A randomized controlled trial of pemoline for attention-deficit/hyperactivity disorder in substance-abusing adolescents.
Riggs PD; Hall SK; Mikulich-Gilbertson SK; Lohman M; Kayser A
J Am Acad Child Adolesc Psychiatry; 2004 Apr; 43(4):420-9. PubMed ID: 15187802
[TBL] [Abstract][Full Text] [Related]
9. Attention-deficit/hyperactivity disorder and early-onset substance use disorders.
Wilson JJ; Levin FR
J Child Adolesc Psychopharmacol; 2005 Oct; 15(5):751-63. PubMed ID: 16262592
[TBL] [Abstract][Full Text] [Related]
10. Substance use disorders in association with attention-deficit/hyperactivity disorder, co-morbid mental disorders, and medication in a nationwide sample.
Steinhausen HC; Bisgaard C
Eur Neuropsychopharmacol; 2014 Feb; 24(2):232-41. PubMed ID: 24314850
[TBL] [Abstract][Full Text] [Related]
11. Health-related quality of life in children and adolescents who have a diagnosis of attention-deficit/hyperactivity disorder.
Klassen AF; Miller A; Fine S
Pediatrics; 2004 Nov; 114(5):e541-7. PubMed ID: 15520087
[TBL] [Abstract][Full Text] [Related]
12. Substance abuse in patients with attention-deficit hyperactivity disorder : therapeutic implications.
Schubiner H
CNS Drugs; 2005; 19(8):643-55. PubMed ID: 16097847
[TBL] [Abstract][Full Text] [Related]
13. Effect of Past Pharmacotherapy for Attention-Deficit/Hyperactivity Disorder on Substance Use Disorder.
Coetzee C; Schellekens AFA; Truter I; Meyer A
Eur Addict Res; 2023; 29(1):9-18. PubMed ID: 36349763
[TBL] [Abstract][Full Text] [Related]
14. Treatments for Adolescents With Comorbid ADHD and Substance Use Disorder: A Systematic Review.
Zaso MJ; Park A; Antshel KM
J Atten Disord; 2020 Jul; 24(9):1215-1226. PubMed ID: 25655767
[No Abstract] [Full Text] [Related]
15. Risk behaviours among substance use disorder treatment seekers with and without adult ADHD symptoms.
Kaye S; Gilsenan J; Young JT; Carruthers S; Allsop S; Degenhardt L; van de Glind G; van den Brink W
Drug Alcohol Depend; 2014 Nov; 144():70-7. PubMed ID: 25193717
[TBL] [Abstract][Full Text] [Related]
16. Irish adolescents with ADHD and comorbid substance use disorder.
Edokpolo O; Nkire N; Smyth BP
Ir J Psychol Med; 2010 Sep; 27(3):148-151. PubMed ID: 30282206
[TBL] [Abstract][Full Text] [Related]
17. Investigating the efficacy of integrated cognitive behavioral therapy for adult treatment seeking substance use disorder patients with comorbid ADHD: study protocol of a randomized controlled trial.
van Emmerik-van Oortmerssen K; Vedel E; Koeter MW; de Bruijn K; Dekker JJ; van den Brink W; Schoevers RA
BMC Psychiatry; 2013 May; 13():132. PubMed ID: 23663651
[TBL] [Abstract][Full Text] [Related]
18. Prevalence of attention-deficit hyperactivity disorder in substance use disorder patients: a meta-analysis and meta-regression analysis.
van Emmerik-van Oortmerssen K; van de Glind G; van den Brink W; Smit F; Crunelle CL; Swets M; Schoevers RA
Drug Alcohol Depend; 2012 Apr; 122(1-2):11-9. PubMed ID: 22209385
[TBL] [Abstract][Full Text] [Related]
19. Methylphenidate doses in Attention Deficit/Hyperactivity Disorder and comorbid substance use disorders.
Skoglund C; Brandt L; D'Onofrio B; Larsson H; Franck J
Eur Neuropsychopharmacol; 2017 Nov; 27(11):1144-1152. PubMed ID: 28935267
[TBL] [Abstract][Full Text] [Related]
20. The diagnostic accuracy of attention-deficit/hyperactivity disorder in adults with substance use disorders.
Fatseas M; Debrabant R; Auriacombe M
Curr Opin Psychiatry; 2012 May; 25(3):219-25. PubMed ID: 22449768
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
